Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The rapidly expanding discipline of pharmacogenetics has helped to explain the mechanisms of susceptibility to several adverse drug reactions. The molecular details of the 'classical' adverse reactions, including malignant hyperthermia, haemolysis in patients with glucose-6-phosphatase deficiency, and acute porphyrias, have become clearer. In addition, associations have emerged between adverse reactions and various polymorphisms that affect drug action. Examples include associations between the human leucocyte-associated antigen HLA B*5701 and hypersensitivity reactions to flucloxacillin and to the HIV protease inhibitor abacavir; between HLA B*1502 and toxic epidermal necrolysis induced in Han Chinese by antiepileptic drugs; between ion-channel mutations and drug-induced torsade de pointes; and between alterations in mitochondrial DNA and several rare adverse effects. The task of identifying individuals susceptible to adverse drug reactions should gradually become easier as more pharmacogenetic associations are described. © 2010 Lippincott Williams & Wilkins.

Original publication

DOI

10.1097/FAD.0b013e328340bc88

Type

Journal article

Journal

Adverse Drug Reaction Bulletin

Publication Date

01/01/2010

Pages

1015 - 1018